Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jel… Read more
Jia Jie Biomedical Co Ltd (4109) - Total Assets
Latest total assets as of September 2025: NT$1.84 Billion TWD
Based on the latest financial reports, Jia Jie Biomedical Co Ltd (4109) holds total assets worth NT$1.84 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jia Jie Biomedical Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Jia Jie Biomedical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jia Jie Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jia Jie Biomedical Co Ltd's total assets of NT$1.84 Billion consist of 23.5% current assets and 76.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.6% |
| Accounts Receivable | NT$40.84 Million | 2.8% |
| Inventory | NT$24.49 Million | 1.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Jia Jie Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jia Jie Biomedical Co Ltd's current assets represent 23.5% of total assets in 2024, a decrease from 27.9% in 2015.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2024, down from 12.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 2.8% of total assets.
Jia Jie Biomedical Co Ltd Competitors by Total Assets
Key competitors of Jia Jie Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Jia Jie Biomedical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Jia Jie Biomedical Co Ltd generates 0.36x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Jia Jie Biomedical Co Ltd generates $ 14.26 in net profit.
Jia Jie Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.93 | 3.22 | 4.79 |
| Quick Ratio | 3.79 | 2.93 | 4.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$442.44 Million | NT$ 236.62 Million | NT$ 300.42 Million |
Jia Jie Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jia Jie Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.99 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | NT$1.48 Billion |
| Market Capitalization | $36.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jia Jie Biomedical Co Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jia Jie Biomedical Co Ltd's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jia Jie Biomedical Co Ltd (2015–2024)
The table below shows the annual total assets of Jia Jie Biomedical Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.48 Billion | +4.91% |
| 2023-12-31 | NT$1.41 Billion | +40.73% |
| 2022-12-31 | NT$1.00 Billion | -1.71% |
| 2021-12-31 | NT$1.02 Billion | +3.23% |
| 2020-12-31 | NT$989.41 Million | +15.61% |
| 2019-12-31 | NT$855.81 Million | -23.49% |
| 2018-12-31 | NT$1.12 Billion | -15.33% |
| 2017-12-31 | NT$1.32 Billion | -19.80% |
| 2016-12-31 | NT$1.65 Billion | +4.33% |
| 2015-12-31 | NT$1.58 Billion | -- |